
MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications
TORONTO and TAIPEI, June 12, 2025 /PRNewswire/ — MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor, Healtdeva Company Ltd., congratulate researchers at Shuang-Ho Hospital in Taipei, Taiwan on their publication of groundbreaking findings using MolecuLight. The clinical study demonstrates the transformative impact of MolecuLight’s i:X® device on the management of deep sternal wound infections (DSWI), showcasing significantly improved patient outcomes alongside cost savings and reduced burden on the healthcare system.